Hate to state the bleeding obvious...
This stock is a high risk, high reward stock.
You only invest in these stocks with money you can afford to lose.
The real problem is the cost and difficulty of human trials.
Small numbers have too many potential variables and limited opportunity to tweak doses, delivery methods, and so many other potential variables (sub-optimal sample space)
Because of this, in reality this trial only ever had the ability to produce two valid outcomes...
1. It works
2. Needs more work
A negative result proves very little other than "needs more work".
The good news for me is that at 4 cents it's now within the scope of my "can afford to lose" range.
My only concern would be that they run out of cash before they get a positive result.
Just my thoughts.
Waiting for the teleconference.
IMO
DYOR!!
Ann: Results of LCT Parkinsons trial require further analysis, page-63
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
